
5
Details of the capitalisation of
development expenditures and
development expenditures in progress
(including information on the results of the
impairment test performed) are described
in Notes 2.1, 2.2, 2.3, 2.4 to the
consolidated financial statements, and
with regard to accounting policy are
described in the notes to the consolidated
financial statements.
The issue was considered to be a key audit
matter due to the scale of the work carried
out, its impact on the Group's operations
and the materiality of the amounts
involved, as well as the fact that the
manner in which they are recognised in the
consolidated financial statements requires
significant management judgement.
assessment of the prepared
impairment test in terms of
mathematical correctness,
reasonableness of the key parameters
adopted by the Group, compliance of
the financial projections with the
approved financial plan and sensitivity
of the test to a change in the assumed
level of cash flows and the discount
rate,
discussion with the Parent Company's
Management Board and other
authorised persons of the key
assumptions included in the
impairment test,
analysis of the disclosures included in
the consolidated financial statements
in relation to completed development
work and development expenditure in
progress.
Sales revenue
The procedures we carried out at the stage
of getting to know the Group and the
analysis of the data resulted in us assigning
risks to the recognition and recognition of
sales revenue.
The risk of incorrect revenue recognition
may arise in particular from fraudulent
recognition of revenue from the sale of
products and services in the wrong period.
Disclosures regarding details of revenue
items are presented in Notes 24.1, 24.2,
24.3 and 24.4 to the consolidated financial
statements, and regarding accounting
policies are described in the notes to the
consolidated financial statements.
The issue was considered to be a key audit
matter due to the materiality of the
amounts and the fact that the manner in
which revenue is recognised and
recognised in the consolidated financial
statements requires significant estimates
and management judgement.
Our procedures for addressing the key risks
identified included:
reviewing the accounting policies in the
revenue recognition section and
assessing the compliance of these
policies with IFRS 15,
understanding of the sales process and
the correctness of the design and
implementation of the internal control
system in this area,
analytical procedures consisting in
particular of the analysis of monthly
data and trends,
detailed plausibility checks on sales
recognised during the year based on a
selected sample,
verification of a sample of transactions
from December 2023/January 2024
and independent assessment of the
correctness of revenue recognition to
the source documents for the
transactions,